NASDAQ:FULC
Fulcrum Therapeutics, Inc. Stock News
$7.75
+0.1000 (+1.31%)
At Close: May 03, 2024
Why Fulcrum Therapeutics Shares Are Soaring Today
01:29pm, Tuesday, 10'th Aug 2021
Fulcrum Therapeutics Inc (NASDAQ: FULC) is surging higher Tuesday after the company reported results from its Phase 1 study of FTX-6058 for sickle cell disease showed proof of mechanism and proof of
Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q2 2021 Results - Earnings Call Transcript
12:54pm, Tuesday, 10'th Aug 2021
Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q2 2021 Results - Earnings Call Transcript
Here's Why Fulcrum Therapeutics Stock Is Shooting Higher Today
10:56am, Tuesday, 10'th Aug 2021
A positive trial readout suggests the company's new drug discovery engine has more potential than expected.
FULC Stock Price Increases Over 60% Pre-Market: Why It Happened
09:13am, Tuesday, 10'th Aug 2021
The stock price of Fulcrum Therapeutics Inc (NASDAQ: FULC) increased by over 60% pre-market. This is why it happened.
Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
07:01am, Tuesday, 10'th Aug 2021
– Reported positive interim results from ongoing Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease demonstrating proof of mechanism and proof of biology –
Will Fulcrum Therapeutics, Inc. (FULC) Report Negative Q2 Earnings? What You Should Know
04:47pm, Tuesday, 03'rd Aug 2021
Fulcrum Therapeutics, Inc. (FULC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation
04:19pm, Wednesday, 12'th May 2021
The FDA has granted Fast Track designation to Fulcrum Therapeutics Inc's (NASDAQ: FULC) losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum is on trac
CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically d
Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q1 2021 Results - Earnings Call Transcript
03:19pm, Saturday, 08'th May 2021
Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q1 2021 Results - Earnings Call Transcript
Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
07:00am, Friday, 07'th May 2021
CAMBRIDGE, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
07:01am, Thursday, 06'th May 2021
– On track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) at virtual FSHD International Research Congress in June 2021 –
Company initiates dosing in Phase 1 healthy volunteer multiple ascending dose (MAD) cohort Company initiates dosing in Phase 1 healthy volunteer multiple ascending dose (MAD) cohort
Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D.
09:29am, Wednesday, 24'th Mar 2021
CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
FULC Stock Price Increases Over 40% Pre-Market: Why It Happened
06:45am, Tuesday, 23'rd Mar 2021
The stock price of Fulcrum Therapeutics Inc (NASDAQ: FULC) increased by over 40% pre-market. This is why it happened.
